Druggable targets for Parkinson’s disease: transcriptomics based Mendelian randomization study DOI Creative Commons
Qiong Lyu, Rong Chen,

Zhengang Qiu

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 28, 2024

Parkinson's disease (PD) is a prevalent neurodegenerative disorder. Currently available drugs for PD, can only relieve the symptoms of but cannot prevent progression and have serious side effects. Other new druggable therapeutic targets PD are needed. First, six GEO datasets with transcriptomic data from substantia nigra (SN) region brain were downloaded to find dysregulated genes in PD. Then, Mendelian randomization (MR) summary statistics-based MR (SMR) analysis conducted using eQTL both tissue blood investigate relationship between gene expression Next, association candidate stage was validated an additional dataset GSE49036. Finally, phenome-wide carried out potential impact on several other complex diseases or traits. Our study revealed 313 differentially expressed that may be directly targetable (FDR-p < 0.1). Through SMR analysis, P2RX7 RNASET2 identified as feasible targets, which highly tissues increased Braak stages increased. Phenome-wide effects targeting RNASET2. This presents genetic support properties RNASET2, will useful developing

Language: Английский

Identifying Novel Drug Targets for Calcific Aortic Valve Disease through Mendelian Randomization DOI
D. Xu, Jin Lü,

Yanfang Yang

et al.

Atherosclerosis, Journal Year: 2025, Volume and Issue: unknown, P. 119110 - 119110

Published: Jan. 1, 2025

Language: Английский

Citations

1
Genetic susceptibility and potential therapeutic targets of unruptured intracranial aneurysms: a genome-wide study based on Mendelian randomization DOI Creative Commons
Shuming Liu,

Huiyuan Guan,

Feng Wang

et al.

Clinical Neurology and Neurosurgery, Journal Year: 2025, Volume and Issue: 249, P. 108749 - 108749

Published: Jan. 21, 2025

Language: Английский

Citations

0
Targeting Liposome-Driven Inflammation in Gestational Diabetes Mellitus: Insights from Multiomics and Molecular Docking DOI

Yanyan Hu,

Dan Wang, Jizheng Wang

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Druggable targets for Parkinson’s disease: transcriptomics based Mendelian randomization study DOI Creative Commons
Qiong Lyu, Rong Chen,

Zhengang Qiu

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 28, 2024

Parkinson's disease (PD) is a prevalent neurodegenerative disorder. Currently available drugs for PD, can only relieve the symptoms of but cannot prevent progression and have serious side effects. Other new druggable therapeutic targets PD are needed. First, six GEO datasets with transcriptomic data from substantia nigra (SN) region brain were downloaded to find dysregulated genes in PD. Then, Mendelian randomization (MR) summary statistics-based MR (SMR) analysis conducted using eQTL both tissue blood investigate relationship between gene expression Next, association candidate stage was validated an additional dataset GSE49036. Finally, phenome-wide carried out potential impact on several other complex diseases or traits. Our study revealed 313 differentially expressed that may be directly targetable (FDR-p < 0.1). Through SMR analysis, P2RX7 RNASET2 identified as feasible targets, which highly tissues increased Braak stages increased. Phenome-wide effects targeting RNASET2. This presents genetic support properties RNASET2, will useful developing

Language: Английский

Citations

0